Novo Nordisk A/S Sponsored ADR is a healthcare company focused on discovering, developing, manufacturing, and marketing pharmaceutical products. The company’s current business is organized around diabetes and obesity care, where it offers treatments and related devices for chronic metabolic conditions, and rare disease, where it serves patients with specialized therapies for blood disorders and endocrine disorders. Novo Nordisk A/S Sponsored ADR works with patients, healthcare professionals, and care providers across global markets, supplying medicines used in long-term disease management. As a sponsored ADR, it gives investors a U.S.-traded representation of the company’s underlying shares while reflecting the performance of its international healthcare operations. The company is headquartered in Bagsværd, Denmark, and remains a major participant in the global pharmaceutical industry through its focus on chronic disease treatment and specialty care.
WebsiteNovo Alle 1
Bagsvaerd, 2880
Denmark
Management is forecasting a considerable slowdown in its revenue growth.
Novo Nordisk (NVO) concluded the recent trading session at $38.31, signifying a -1.03% move from its prior day's close.
Novo Nordisk (CPSE:NOVO B) entered an exclusive license with Hengrui Pharma for a once-weekly oral GLP-1/GIP dual agonist. Phase 3 CagriSema data delivered new weight management clinical results that add another late-stage asset to Novo Nordisk’s pipeline. The CHMP issued a positive opinion backing Sogroya for idiopathic short stature and supported FREHEMGO for hemophilia A patients. The Hengrui oral GLP-1/GIP deal and new trial wins tell only part of the Novo Nordisk story. We have also...
Novo Nordisk reports lower cardiovascular risk for semaglutide over tirzepatide and secures a $2.6 billion licensing deal.
Novo Nordisk Drops Big Ozempic Finding From 630,000-Patient Study
Investors talking about NVO also mention
| # | Name | Attention |
|---|---|---|
| 1 | Eli Lilly and CompanyLLY | 0.16%+0.07 |
| 2 | MTSR - Metsera, Inc. | —— |
| 3 | Hims & Hers Health, Inc.HIMS | 0.17%+0.1 |
| 4 | UnitedHealth Group IncorporatedUNH | 0%-0.02 |
| 5 | Viking Therapeutics, Inc.VKTX | 0.18%0 |
| 6 | ASML Holding N.V. NY Registered SharesASML | 0.01%-0.02 |
| 7 | Structure Therapeutics Inc. American Depositary SharesGPCR | 0%new |
| 8 | Duolingo, Inc. Class A Common StockDUOL | 0.01%-0.01 |
| 9 | dLocal LimitedDLO | 0%new |
| 10 | Genmab A/S American Depositary SharesGMAB | 0%0 |
What share of all stock conversation is about NVO?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0.14% -0.04 | 0.45% +0.22 | 0.31% +0.08 | 0.49% +0 |
Of the messages about NVO that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | 63.98% +43.07 | 59.82% +6.71 | 68.69% +29.08 | 80.15% +5.1 | ||
| Bearish | 36.02% -43.07 | 40.18% -6.71 | 31.31% -29.08 | 19.85% -5.1 |
Of the messages about NVO that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Earnings | 0% | 0.01% | 15.67% | 7.86% | ||
| Analysts | 8.51% | 45.91% | 38.41% | 33.83% | ||
| Announcements | 81.28% | 6.77% | 5.66% | 7.58% | ||
| Macro | 4.68% | 45.9% | 36.37% | 45.38% | ||
| Technical Analysis | 5.53% | 1.18% | 3.69% | 3.96% | ||
| Controversies | 0% | 0.22% | 0.19% | 1.39% |
Of the messages about NVO, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 80.73% | 88.28% | 63.46% | 52.34% | ||
| Newcomers | 19.27% | 11.72% | 36.54% | 47.66% |